LATHAM & WATKINS LLP

March 6, 2024

VIA EDGAR

Daniel Crawford
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549

Re: Boundless Bio, Inc.

Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted January 23, 2024

CIK No. 0001782303

Dear Mr. Crawford:

We are in receipt of the Staff's letter dated January 29, 2024 with respect to the above-referenced confidential draft Amendment No. 2 to Draft Registration Statement on Form S-1. We are responding to the Staff's comments on behalf of Boundless Bio, Inc. ("Boundless" or the "Company") as set forth below. Simultaneously with the submission of this letter, the Company is publicly filing via EDGAR a Registration Statement on Form S-1 (the "Registration Statement") responding to the Staff's comments and updating the Company's disclosures in the Registration Statement.

The Company's responses set forth in this letter are numbered to correspond to the numbered comments in the Staff's letter. All terms used but not defined herein have the meanings assigned to such terms in the Registration Statement. For ease of reference, we have set forth the Staff's comments and the Company's response for each item below.

Amendment No. 2 to Draft Registration Statement on Form S-1

Prospectus Summary

Our Pipeline and Platform, page 3

1. Please revise your pipeline table here and elsewhere in the registration statement so that it contains no more than two preclinical columns that show a progress bar.

Boundless' Response: The Company has revised the pipeline table on pages 3, 102 and 121 of the Registration Statement in response to the Staff's comment.

12670 High Bluff Drive San Diego, California 92130

Tel: +1.858.523.5400 Fax: +1.858.523.5450

www.lw.com

FIRM / AFFILIATE OFFICES
Austin Milan
Beijing Munich
Boston New York
Brussels Orange County

Century City Paris
Chicago Riyadh
Dubai San Diego
Düsseldorf San Francisco
Frankfurt Seoul

Hamburg Silicon Valley
Hong Kong Singapore
Houston Tel Aviv
London Tokyo

Los Angeles Washington, D.C.

Madrid

March 6, 2024 Page 2

LATHAM & WATKINS LLP

Any comments or questions regarding the foregoing should be directed to the undersigned at (858) 523-3962. Thank you in advance for your cooperation in connection with this matter.

Very truly yours,

/s/ Matthew T. Bush Matthew T. Bush of LATHAM & WATKINS LLP

C: Zachary Hornby, Boundless Bio, Inc.
Jami Rubin, Boundless Bio, Inc.
Jessica Oien, Boundless Bio, Inc.
Cheston J. Larson, Latham & Watkins LLP
Charles S. Kim, Cooley LLP
Denny Won, Cooley LLP